Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Nis Register Study Comparing Seroquel and Seroquel Prolong

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00965536
First received: August 24, 2009
Last updated: February 15, 2011
Last verified: February 2011
  Purpose

The general aim of this non interventional study is to clarify what are the current clinical treatment practices of Quetiapine Immediate Release and Quetiapine Extended Release. The primary objectives of the study are:1.To collect information on the used Quetiapine Immediate Release or Quetiapine Extended Release medication 2.To collect information on duration and number of hospitalisation days 3.Change of GAF points


Condition
Comparing Hospitalisation Time With Seroquel and Seroquel Prolong

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: A Local Non Interventional Retrospective Register Study of the Current Clinical Treatment Practices and the Number of Hospitalization Days With Seroquel or Seroquel Prolong.

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Hospitalisation time [ Time Frame: 2008-2010 ] [ Designated as safety issue: No ]
  • Treatment practice [ Time Frame: 2008-2010 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Primary diagnosis [ Time Frame: 2008-2010 ] [ Designated as safety issue: No ]
  • Medication at the end of hospitalisation [ Time Frame: 2008-2010 ] [ Designated as safety issue: No ]
  • GAF rating points [ Time Frame: 2008-2010 ] [ Designated as safety issue: No ]

Estimated Enrollment: 200
Study Start Date: August 2009
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Seroquel
2
Seroquel Prolong

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

South Karelia Central Hospital in-patients

Criteria

Inclusion Criteria:

  • Medication: Seroquel or Seroquel Prolong
  • Diagnosis: F20-F29 or F30-F31 (ICD-10)
  • In-patient

Exclusion Criteria:

  • None
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00965536

Locations
Finland
Research Site
Lappeenranta, Finland
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Yrjö Ovaskainen Medical Affairs Manager, MD, psychiatrist
Principal Investigator: Kari Hänninen MD, psychiatrist
  More Information

No publications provided

Responsible Party: MC MD, AstraZeneca
ClinicalTrials.gov Identifier: NCT00965536     History of Changes
Other Study ID Numbers: NIS-NFI-SER-2009/1
Study First Received: August 24, 2009
Last Updated: February 15, 2011
Health Authority: Finland: Finnish Medicines Agency

Keywords provided by AstraZeneca:
Schizophrenia
Bipolar Disorder
Manic Disorder
Register study
Quetiapine
Quetiapine Prolong
Seroquel
Seroquel Prolong
Seroquel XR
In-patient

Additional relevant MeSH terms:
Quetiapine
Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents

ClinicalTrials.gov processed this record on November 25, 2014